PharmaPoint: Atopic Dermatitis - Italy Drug Forecast and Market Analysis to 2022
Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.
By the mid-to-late term of GlobalData’s 2012 to 2022 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the moderate and severe treatment landscape.
Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.
The key growth drivers in Italy will be systemic products, in particular cyclosporine and those within the corticosteroids class. The increasing uptake of these market drivers will be most notable in the moderate and severe patient segments. In addition, Italian dermatologists surveyed by GlobalData in July 2013 anticipate growing uptake of off-label biologic Xolair within their severe population.
Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Italy from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting Italy Atopic Dermatitis market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in Italy